Oxpro Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 1.00 Cr
- Company Age 4 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 48.67%
- Profit Growth 68.19%
- Ebitda 72.17%
- Net Worth 136.49%
- Total Assets 70.91%
About Oxpro Pharma
Oxpro Pharma Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 June 2020 (Four years and seven months 29 days old ). Its registered office is in Ranchi, Jharkhand, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Kumar, Saurabh Vidyarthi, and Sarita Kumari serve as directors at the Company.
Company Details
-
Location
Ranchi, Jharkhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909JH2020PTC014366
-
Company No.
014366
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Jun 2020
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Jharkhand
Industry
Who are the key members and board of directors at Oxpro Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Kumar
|
Whole-Time Director | 04-Jun-2020 | Current |
|
Saurabh Vidyarthi
|
Whole-Time Director | 04-Jun-2020 | Current |
|
Sarita Kumari
|
Additional Director | 02-Dec-2021 | Current |
Financial Performance of Oxpro Pharma.
Oxpro Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 48.67% increase. The company also saw a substantial improvement in profitability, with a 68.19% increase in profit. The company's net worth Soared by an impressive increase of 136.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oxpro Pharma?
In 2021, Oxpro Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Oxford Ct Scan Centre Private LimitedSanjay Kumar is a mutual person
-
Osmonix Pharma Private Limited
Sanjay Kumar is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oxpro Pharma?
Oxpro Pharma has a workforce of 80 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oxpro Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oxpro Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.